Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Clin Microbiol Infect ; 29(7): 891-896, 2023 Jul.
Article in English | MEDLINE | ID: mdl-36871826

ABSTRACT

OBJECTIVES: To assess the value of screening for Clostridioides difficile colonization (CDC) at hospital admission in an endemic setting. METHODS: A multi-centre study was conducted at four hospitals located across the Netherlands. Newly admitted patients were screened for CDC. The risk of development of Clostridioides difficile infection (CDI) during admission and 1-year follow-up was assessed in patients with and without colonization. C. difficile isolates from patients with colonization were compared with isolates from incident CDI cases using core genome multi-locus sequence typing to determine whether onwards transmission had occurred. RESULTS: CDC was present in 108 of 2211 admissions (4.9%), whereas colonization with a toxigenic strain (toxigenic Clostridoides difficile colonization [tCDC]) was present in 68 of 2211 admissions (3.1%). Among these 108 patients with colonization, diverse PCR ribotypes were found and no 'hypervirulent' PCR ribotype 027 (RT027) was detected (95% CI, 0-0.028). None of the patients with colonization developed CDI during admission (0/49; 95% CI, 0-0.073) or 1-year follow-up (0/38; 95% CI, 0-0.93). Core genome multi-locus sequence typing identified six clusters with genetically related isolates from patients with tCDC and CDI; however, in these clusters, only one possible transmission event from a patient with tCDC to a patient with CDI was identified based on epidemiological data. CONCLUSION: In this endemic setting with a low prevalence of 'hypervirulent' strains, screening for CDC at admission did not detect any patients with CDC who progressed to symptomatic CDI and detected only one possible transmission event from a patient with colonization to a patient with CDI. Thus, screening for CDC at admission is not useful in this setting.


Subject(s)
Clostridioides difficile , Clostridium Infections , Humans , Clostridioides difficile/genetics , Clostridioides/genetics , Multilocus Sequence Typing , Hospitalization , Clostridium Infections/diagnosis , Clostridium Infections/epidemiology , Clostridium Infections/microbiology , Hospitals , Ribotyping
2.
Eur Heart J Case Rep ; 3(4): 1-6, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31912002

ABSTRACT

BACKGROUND: Whipple's disease is caused by Tropheryma whipplei and causes a self-limiting gastrointestinal infection. The majority of the population is an asymptomatic carrier, however, in some patients, it causes an invasive infection with for example arthritis, endocarditis, or involvement of the eyes. CASE SUMMARY: This case describes a man with long-lasting complaints of progressive dyspnoea caused by heart failure due to total destruction of the aortic and mitral valve as a result of T. whipplei endocarditis, diagnosed with serum polymerase chain reaction. The patient was treated with ceftriaxone and prolonged co-trimoxazole therapy and surgical replacement of the aortic and mitral valve. He was discharged to a rehabilitation centre. DISCUSSION: Tropheryma whipplei is one of the possible microorganisms classified as causing blood culture-negative endocarditis, with predominantly afebrile patients that do not fulfil the Dukes criteria, which makes it difficult to diagnose. Polymerase chain reaction is the cornerstone of the diagnosis. It requires long-term antibiotic treatment up to 12 months. It is recommended by the European Society of Cardiology to discuss treatment in an Endocarditis Team because Whipple's endocarditis has only rarely been described in the literature previously. Whipple's endocarditis has high mortality and relapse rates.

3.
J Bone Jt Infect ; 3(4): 203-206, 2018.
Article in English | MEDLINE | ID: mdl-30416944

ABSTRACT

According to the relevant literature, prosthetic joint infections caused by Listeria monocytogenes require two stage revision surgery or prosthesis removal for a successful outcome. We present the case of a patient who suffered such an infection after Total Knee Replacement surgery and was successfully treated with antibiotics, joint lavage, debridement and retention of the prosthesis.

4.
J Surg Case Rep ; 2018(8): rjy188, 2018 Aug.
Article in English | MEDLINE | ID: mdl-30093990

ABSTRACT

We present a case of 45-year-old male with acute phlegmonous gastritis (APG) based on a hemolytic group A Streptococcus. APG is a rare and often a potentially fatal disease, which is characterized by a severe bacterial infection of the gastric wall. Because APG is a rapidly progressive disease, it comes with high mortality rates. Patients with an early diagnosis may undergo successful treatment and have a survival benefit. As soon as the diagnosis of APG is suspected, aggressive and adequate antibiotic treatment in combination with surgical intervention should be considered.

5.
J Clin Microbiol ; 55(2): 403-411, 2017 02.
Article in English | MEDLINE | ID: mdl-27852676

ABSTRACT

Recent evidence shows that patients asymptomatically colonized with Clostridium difficile may contribute to the transmission of C. difficile in health care facilities. Additionally, these patients may have a higher risk of developing C. difficile infection. The aim of this study was to compare a commercially available PCR directed to both toxin A and B (artus C. difficile QS-RGQ kit CE; Qiagen), an enzyme-linked fluorescent assay to glutamate dehydrogenase (GDH ELFA) (Vidas, bioMérieux), and an in-house-developed PCR to tcdB, with (toxigenic) culture of C. difficile as the gold standard to detect asymptomatic colonization. Test performances were evaluated in a collection of 765 stool samples obtained from asymptomatic patients at admission to the hospital. The C. difficile prevalence in this collection was 5.1%, and 3.1% contained toxigenic C. difficile Compared to C. difficile culture, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the C. difficile GDH ELFA were 87.2%, 91.2%, 34.7%, and 99.3%, respectively. Compared with results of toxigenic culture, the sensitivity, specificity, PPV, and NPV of the commercially available PCR and the in-house PCR were 95.8%, 93.4%, 31.9%, 99.9%, and 87.5%, 98.8%, 70%, and 99.6%, respectively. We conclude that in a low-prevalence setting of asymptomatically colonized patients, both GDH ELFA and a nucleic acid amplification test can be applied as a first screening test, as they both display a high NPV. However, the low PPV of the tests hinders the use of these assays as stand-alone tests.


Subject(s)
Bacteriological Techniques/methods , Carrier State/diagnosis , Clostridioides difficile/isolation & purification , Clostridium Infections/diagnosis , Feces/microbiology , Immunoassay/methods , Polymerase Chain Reaction/methods , Bacterial Proteins/genetics , Bacterial Toxins/genetics , Carrier State/microbiology , Clostridioides difficile/genetics , Clostridium Infections/microbiology , Enterotoxins/genetics , Hospitals , Humans , Predictive Value of Tests , Sensitivity and Specificity
6.
Lancet Infect Dis ; 16(7): 847-856, 2016 Jul.
Article in English | MEDLINE | ID: mdl-26947617

ABSTRACT

BACKGROUND: Antimicrobial stewardship is advocated to improve the quality of antimicrobial use. We did a systematic review and meta-analysis to assess whether antimicrobial stewardship objectives had any effects in hospitals and long-term care facilities on four predefined patients' outcomes: clinical outcomes, adverse events, costs, and bacterial resistance rates. METHODS: We identified 14 stewardship objectives and did a separate systematic search for articles relating to each one in Embase, Ovid MEDLINE, and PubMed. Studies were included if they reported data on any of the four predefined outcomes in patients in whom the specific antimicrobial stewardship objective was assessed and compared the findings in patients in whom the objective was or was not met. We used a random-effects model to calculate relative risk reductions with relative risks and 95% CIs. FINDINGS: We identified 145 unique studies with data on nine stewardship objectives. Overall, the quality of evidence was generally low and heterogeneity between studies was mostly moderate to high. For the objectives empirical therapy according to guidelines, de-escalation of therapy, switch from intravenous to oral treatment, therapeutic drug monitoring, use of a list of restricted antibiotics, and bedside consultation the overall evidence showed significant benefits for one or more of the four outcomes. Guideline-adherent empirical therapy was associated with a relative risk reduction for mortality of 35% (relative risk 0·65, 95% CI 0·54-0·80, p<0·0001) and for de-escalation of 56% (0·44, 0·30-0·66, p<0·0001). Evidence of effects was less clear for adjusting therapy according to renal function, discontinuing therapy based on lack of clinical or microbiological evidence of infection, and having a local antibiotic guide. We found no reports for the remaining five stewardship objectives or for long-term care facilities. INTERPRETATION: Our findings of beneficial effects on outcomes with nine antimicrobial stewardship objectives suggest they can guide stewardship teams in their efforts to improve the quality of antibiotic use in hospitals. FUNDING: Dutch Working Party on Antibiotic Policy and Netherlands National Institute for Public Health and the Environment.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents/therapeutic use , Bacterial Infections/drug therapy , Drug Resistance, Microbial , Anti-Bacterial Agents/adverse effects , Drug Utilization/standards , Hospitals , Humans , Netherlands , Patient Safety
7.
Mycoses ; 59(2): 101-7, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26648179

ABSTRACT

A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.


Subject(s)
Amphotericin B/therapeutic use , Aspergillosis/diagnosis , Aspergillosis/drug therapy , Aspergillus fumigatus/drug effects , Voriconazole/therapeutic use , Antifungal Agents/therapeutic use , Aspergillosis/epidemiology , Aspergillus fumigatus/isolation & purification , Drug Resistance, Fungal , Humans , Netherlands/epidemiology , Surveys and Questionnaires , Voriconazole/pharmacology
8.
J Arthroplasty ; 28(2): 375.e13-5, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22810005

ABSTRACT

Fungal prosthetic joint infections are rare and difficult to treat. There is an ongoing discussion about the type and duration of antifungal treatment and the necessity of prosthesis removal. We report the first European case of an infected total knee arthroplasty with Coccidioides immitis. Treatment consisted of lifelong treatment with oral fluconazole at a dose of 400 mg/d, without total knee arthroplasty removal. After 6 months, the initial complaints of pain and swelling were completely resolved. This case report clearly states that a travel history and culturing for fungi are helpful in patients with persisting complaints after joint arthroplasty.


Subject(s)
Antifungal Agents/administration & dosage , Arthroplasty, Replacement, Knee/adverse effects , Coccidioides , Coccidioidomycosis/drug therapy , Fluconazole/administration & dosage , Prosthesis-Related Infections/drug therapy , Aged , Drug Administration Schedule , Female , Humans , Knee Prosthesis/adverse effects , Knee Prosthesis/microbiology , Prosthesis-Related Infections/microbiology , Travel
9.
FEMS Microbiol Lett ; 249(2): 207-9, 2005 Aug 15.
Article in English | MEDLINE | ID: mdl-16006058

ABSTRACT

A hemolytic bystander assay was used to assess the functional serum mannose-binding lectin (MBL) activating capacity of five isolates of Moraxella catarrhalis obtained from children who suffered recurrent acute otitis media episodes. Results showed that this organism is only a poor activator of the lectin pathway of complement activation, with subsequent consequences for the etiology of otitis media by this organism.


Subject(s)
Complement Pathway, Mannose-Binding Lectin , Mannose-Binding Lectin/blood , Moraxella catarrhalis/physiology , Otitis Media/microbiology , Child , Humans , Species Specificity
10.
Plasmid ; 53(3): 263-8, 2005 May.
Article in English | MEDLINE | ID: mdl-15848230

ABSTRACT

A preliminary screening study of six Moraxella catarrhalis isolates from primary school children in the Netherlands identified a small 3.5 kb plasmid (pEMCJH03), containing four open reading frames, which encoded three mobilizing and one replicase protein. Insertion of a kanamycin containing transposon (yielding pEMCJH04) allowed selection and isolation of the plasmid in Escherichia coli. Natural transformation of pEMCJH04 into M. catarrhalis was successful for 25% (3/12) of non-isogenic isolates, with no link between (lack of) transformability and genetic lineage or (lack of) transformability and complement phenotype, though the transformation efficiency was found to be rather low at approximately 615CFU/microg (range=60-1040CFU/microg ). This is only the second publication detailing a plasmid isolated from this important respiratory pathogen, and the ability to clone and express foreign proteins in M. catarrhalis using pEMCJH04 could help in the development of a vaccine expression vector, as well as providing a useful tool for studying promoter activity and in complementation studies of gene knockout mutants.


Subject(s)
Cloning, Molecular , Genetic Vectors , Moraxella catarrhalis/genetics , Plasmids/genetics , Plasmids/isolation & purification , Bacterial Proteins , Base Sequence , Child , Chromosome Mapping , Chromosomes, Bacterial , DNA Transposable Elements , DNA, Bacterial , Escherichia coli/genetics , Genes, Bacterial , Humans , Kanamycin/chemistry , Molecular Sequence Data , Moraxella catarrhalis/pathogenicity , Mutagenesis, Insertional , Netherlands , Open Reading Frames , Plasmids/chemistry , Repetitive Sequences, Nucleic Acid , Selection, Genetic , Species Specificity , Transformation, Bacterial
11.
J Clin Microbiol ; 41(7): 3017-21, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12843036

ABSTRACT

Nonbullous impetigo is a common skin infection in children and is frequently caused by Staphylococcus aureus. Staphylococcal toxins and especially exfoliative toxin A are known mediators of bullous impetigo in children. It is not known whether this is also true for nonbullous impetigo. We set out to analyze clonality among clinical isolates of S. aureus from children with nonbullous impetigo living in a restricted geographical area in The Netherlands. We investigated whether staphylococcal nasal carriage and the nature of the staphylococcal strains were associated with the severity and course of impetigo. Bacterial isolates were obtained from the noses and wounds of children suffering from impetigo. Strains were genetically characterized by pulsed-field gel electrophoresis-mediated typing and binary typing, which was also used to assess toxin gene content. In addition, a detailed clinical questionnaire was filled in by each of the participating patients. Staphylococcal nasal carriage seems to predispose the patients to the development of impetigo, and 34% of infections diagnosed in the Rotterdam area are caused by one clonal type of S. aureus. The S. aureus strains harbor the exfoliative toxin B (ETB) gene as a specific virulence factor. In particular, the numbers (P = 0.002) and sizes (P < 0.001) of the lesions were increased in patients infected with an ETB-positive strain. Additional predictors of disease severity and development could be identified. The presence of a staphylococcal plasmid encoding multiple antibiotic resistance traits, as detected by binary typing, was associated with a reduction in the cure rate. Our results recognize that a combination of staphylococcal virulence and resistance genes rather than a single gene determines the development and course of nonbullous impetigo. The identification of these microbial genetic markers, which are predictive of the severity and the course of the disease, will facilitate guided individualized antimicrobial therapy in the future.


Subject(s)
Impetigo/physiopathology , Severity of Illness Index , Staphylococcus aureus/classification , Staphylococcus aureus/genetics , Anti-Bacterial Agents/therapeutic use , Bacterial Toxins , Child , Child, Preschool , Drug Resistance, Multiple, Bacterial/genetics , Exfoliatins/genetics , Exotoxins , Fusidic Acid/therapeutic use , Genetic Markers , Humans , Impetigo/drug therapy , Impetigo/microbiology , Leukocidins/genetics , Nose/microbiology , Plasmids , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Staphylococcal Infections/physiopathology , Staphylococcus aureus/isolation & purification , Staphylococcus aureus/pathogenicity , Virulence/genetics
12.
Eur J Pediatr ; 162(7-8): 514-516, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12740695

ABSTRACT

UNLABELLED: The role of Mycoplasma hominisas a causative agent for neonatal sepsis and meningitis is still unclear. Meningitis secondary to M. hominisis well-described in the literature; however, M. hominiscan also be isolated from cerebrospinal fluid (CSF) obtained from infants without signs of meningitis. We present a case of a full-term infant with meningo-encephalitis with seizures, epileptic activity on the EEG, inflammation of brain tissue on a CT scan, and cloudy CSF containing elevated cell counts, decreased glucose levels and elevated protein levels. M. hominiswas identified from the CSF by culture and by polymerase chain reaction (PCR) as the only possible causative agent. Furthermore, while empiric antibiotic and antiviral treatment for neonatal sepsis had failed, the meningo-encephalitis promptly responded upon antibiotic treatment with ciprofloxacin (20 mg/kg per day i.v.), to which M. hominisis susceptible. CONCLUSION: A meningo-encephalitis developed due to infection with M. hominisin a full-term infant, from which he recovered rapidly after start of treatment with ciprofloxacin.


Subject(s)
Anti-Infective Agents/therapeutic use , Ciprofloxacin/therapeutic use , Meningoencephalitis/drug therapy , Mycoplasma Infections/drug therapy , Humans , Infant, Newborn , Male , Meningoencephalitis/microbiology , Mycoplasma hominis
13.
Vaccine ; 21(11-12): 1118-24, 2003 Mar 07.
Article in English | MEDLINE | ID: mdl-12559789

ABSTRACT

Intra-genomic variation in the uspA1 and uspA2 genes of Moraxella catarrhalis was studied using pulsed field gel electrophoresis (PFGE) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. From a set of 91 M. catarrhalis isolates, 19 pairs of PFGE identical isolates were found. Five pairs originated from otitis non-prone children, 11 pairs from otitis prone children and for 3 pairs, one of the pair originated from an otitis prone and the other from an otitis non-prone child. No particular M. catarrhalis isolate was associated with either the otitis prone or non-prone children. One of these 19 pairs of isolates was found to exhibit both uspA1 and uspA2 intra-genomic variation, whilst another pair exhibited uspA2 intra-genomic variation only. Sequence data obtained from these variants showed that PCR-RFLP pattern differences reflected actual changes in predicted amino acid composition and that minor amino acid changes in a 23 base pair "NINNIY" repeat region (a conserved UspA1 and UspA2 binding site for the neutralising antibody mAb17C7) occurred. Variation in the uspA2 5' non-coding "AGAT" repeat region was also observed. These results may have implications for future M. catarrhalis vaccines comprising UspA1 or UspA2 components.


Subject(s)
Antigens, Bacterial/genetics , Bacterial Outer Membrane Proteins/genetics , Genome, Bacterial , Moraxella catarrhalis/genetics , Otitis Media/microbiology , Amino Acid Sequence , Antigens, Bacterial/immunology , Bacterial Outer Membrane Proteins/immunology , Child, Preschool , Complement System Proteins/immunology , DNA, Bacterial/genetics , Electrophoresis, Gel, Pulsed-Field , Epitopes/genetics , Epitopes/immunology , Female , Genetic Variation , Humans , Infant , Male , Molecular Sequence Data , Moraxella catarrhalis/classification , Moraxella catarrhalis/isolation & purification , Otitis Media/prevention & control , Phylogeny , Polymerase Chain Reaction , Polymorphism, Genetic , Polymorphism, Restriction Fragment Length , Recurrence , Repetitive Sequences, Nucleic Acid , Sequence Alignment , Sequence Analysis, DNA , Sequence Homology, Amino Acid
14.
Infect Immun ; 70(12): 7022-32, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12438382

ABSTRACT

Proteus mirabilis infection often leads to stone formation. We evaluated how bacterium-mucin adhesion, invasion, and intracellular crystal formation are related to antibiotic sensitivity and may cause frequent stone formation in enterocystoplasties. Five intestinal (Caco-2, HT29, HT29-18N2, HT29-FU, and HT29-MTX) and one ureter cell line (SV-HUC-1) were incubated in artificial urine with five Proteus mirabilis strains. Fluorescence-activated cell sorting (FACS), laser scanning microscopy, and electron microscopy evaluated cellular adhesion and/or invasion, pathologic changes to mitochondria, and P. mirabilis-mucin colocalization (MUC2 and MUC5AC). An MTT (thiazolyl blue tetrazolium bromide) assay and FACS analysis of caspase-3 evaluated the cellular response. Infected cells were incubated with antibiotics at dosages representing the expected urinary concentrations in a 10-year-old, 30-kg child to evaluate bacterial invasion and survival. All cell lines showed colocalization of P. mirabilis with human colonic mucin (i.e., MUC2) and human gastric mucin (i.e., MUC5AC). The correlation between membrane mucin expression and invasion was significant and opposite for SV-HUC-1 and HT29-MTX. Microscopically, invasion by P. mirabilis with intracellular crystal formation and mitochondrial damage was found. Double membranes surrounded bacteria in intestinal cells. Relative resistance to cotrimoxazole and augmentin was found in the presence of epithelial cells. Ciprofloxacin and gentamicin remained effective. Membrane mucin expression was correlated with relative antibiotic resistance. Cell invasion by P. mirabilis and mucin- and cell type-related distribution and response differences indicate bacterial tropism that affects crystal formation and mucosal presence. Bacterial invasion seems to have cell type-dependent mechanisms and prolong bacterial survival in antibiotic therapy, giving a new target for therapeutic optimalization of antibiotic treatment.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Intestines/microbiology , Proteus mirabilis/drug effects , Proteus mirabilis/pathogenicity , Ureter/microbiology , Bacterial Adhesion , Cell Line , Child , Culture Media , Humans , Intestines/cytology , Microscopy, Confocal , Microscopy, Electron , Mucins/metabolism , Proteus Infections/microbiology , Ureter/cytology , Urinary Calculi , Urine/microbiology
15.
Clin Pharmacol Ther ; 71(5): 349-58, 2002 May.
Article in English | MEDLINE | ID: mdl-12011820

ABSTRACT

OBJECTIVE: Our objective was to individualize tobramycin dosing regimens in neonates of various gestational ages with use of early therapeutic drug monitoring. METHODS: This study was performed in neonatal patients with suspected septicemia in the first week of life. All patients received tobramycin, 4 mg/kg per dose, as a 30-minute intravenous infusion, with a gestational age-related initial interval of 48 hours (<32 weeks), 36 hours (32-36 weeks), and 24 hours (> or =37 weeks). The target serum peak and trough serum concentrations were 5 to 10 mg/L and 0.5 mg/L, respectively. Serum trough samples and 1- and 6-hour samples were taken after the first dose. Tobramycin concentrations were used to obtain gestational age-dependent population models with nonparametric expectation maximization software. To investigate the effect of timing of sampling in a second group of patients, serum trough samples and 3- and 8-hour samples were taken after the first dose of tobramycin was administered. Serum trough concentrations were predicted by use of linear pharmacokinetics in both groups and by use of the population models with bayesian feedback of 1 or 2 serum concentrations in the second group. These predicted concentrations were compared with actual serum trough concentrations. The predictive performance of the 1- to 6-hour and 3- to 8-hour models and the population models were compared with a gestational age-related model without therapeutic drug monitoring. RESULTS: A total of 247 patients were analyzed: 206 with 1- to 6-hour serum samples and 41 with 3- to 8-hour serum samples. Peak serum concentrations were above 5 mg/L in 90.8% of cases, and trough serum concentrations were above 1 mg/L in 25.5% of cases. The 3- to 8-hour linear model had a bias of -0.31 mg/L and a precision of 0.48 mg/L, and it performed significantly better than the 1- to 6-hour model. The best nonparametric expectation maximization model had a bias of -0.11 mg/L and a precision of 0.45 mg/L. None of the models yielded a significant improvement of predictive performance over the model without therapeutic drug monitoring. CONCLUSIONS: Routine early therapeutic drug monitoring does not improve the model-based prediction of initial tobramycin dosing intervals in neonates in the first week of life.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Drug Monitoring , Infant, Newborn/blood , Tobramycin/administration & dosage , Tobramycin/therapeutic use , Anti-Bacterial Agents/blood , Drug Administration Schedule , Drug Monitoring/methods , Drug Monitoring/trends , Forecasting , Humans , Linear Models , Tobramycin/blood
16.
Clin Microbiol Rev ; 15(1): 125-44, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11781271

ABSTRACT

Moraxella catarrhalis (formerly known as Branhamella catarrhalis) has emerged as a significant bacterial pathogen of humans over the past two decades. During this period, microbiological and molecular diagnostic techniques have been developed and improved for M. catarrhalis, allowing the adequate determination and taxonomic positioning of this pathogen. Over the same period, studies have revealed its involvement in respiratory (e.g., sinusitis, otitis media, bronchitis, and pneumonia) and ocular infections in children and in laryngitis, bronchitis, and pneumonia in adults. The development of (molecular) epidemiological tools has enabled the national and international distribution of M. catarrhalis strains to be established, and has allowed the monitoring of nosocomial infections and the dynamics of carriage. Indeed, such monitoring has revealed an increasing number of B-lactamase-positive M. catarrhalis isolates (now well above 90%), underscoring the pathogenic potential of this organism. Although a number of putative M. catarrhalis virulence factors have been identified and described in detail, their relationship to actual bacterial adhesion, invasion, complement resistance, etc. (and ultimately their role in infection and immunity), has been established in a only few cases. In the past 10 years, various animal models for the study of M. catarrhalis pathogenicity have been described, although not all of these models are equally suitable for the study of human infection. Techniques involving the molecular manipulation of M. catarrhalis genes and antigens are also advancing our knowledge of the host response to and pathogenesis of this bacterial species in humans, as well as providing insights into possible vaccine candidates. This review aims to outline our current knowledge of M. catarrhalis, an organism that has evolved from an emerging to a well-established human pathogen.


Subject(s)
Moraxella catarrhalis , Adult , Carbohydrate Sequence , Cell Wall/chemistry , Child , Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/microbiology , Humans , Lipopolysaccharides/chemistry , Molecular Sequence Data , Moraxella catarrhalis/classification , Moraxella catarrhalis/genetics , Moraxella catarrhalis/isolation & purification , Moraxella catarrhalis/pathogenicity , Neisseriaceae Infections/epidemiology , Neisseriaceae Infections/immunology , Neisseriaceae Infections/microbiology , Neisseriaceae Infections/physiopathology
17.
BMJ ; 324(7331): 203-6, 2002 Jan 26.
Article in English | MEDLINE | ID: mdl-11809642

ABSTRACT

OBJECTIVE: To test the hypothesis that fusidic acid would not increase the treatment effect of disinfecting with povidone-iodine alone in children with impetigo. DESIGN: Randomised placebo controlled trial. SETTING: General practices in Greater Rotterdam. PARTICIPANTS: 184 children aged 0-12 years with impetigo. MAIN OUTCOME MEASURES: Clinical cure and bacterial cure after one week. RESULTS: After one week of treatment 55% of the patients in the fusidic acid group were clinically cured compared with 13% in the placebo group (odds ratio 12.6, 95% confidence interval 5.0 to 31.5, number needed to treat 2.3). After two weeks and four weeks the differences in cure rates between the two groups had become smaller. More children in the placebo group were non-compliant (12 v 5) and received extra antibiotic treatment (11 v 3), and more children in the placebo group reported adverse effects (19 v 7). Staphylococcus aureus was found in 96% of the positive cultures; no strains were resistant to fusidic acid. CONCLUSIONS: Fusidic acid is much more effective than placebo (when both are given in combination with povidone-iodine shampoo) in the treatment of impetigo. Because of the low rate of cure and high rate of adverse events in the placebo group, the value of povidone-iodine in impetigo can be questioned.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Fusidic Acid/therapeutic use , Impetigo/drug therapy , Anti-Bacterial Agents/adverse effects , Anti-Infective Agents, Local/therapeutic use , Child , Child, Preschool , Double-Blind Method , Drug Therapy, Combination , Family Practice/methods , Female , Follow-Up Studies , Fusidic Acid/adverse effects , Humans , Impetigo/microbiology , Infant , Infant, Newborn , Logistic Models , Male , Ointments , Povidone-Iodine/therapeutic use , Staphylococcus/isolation & purification , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL